I found a case study of using Arimidex (Anastrozole) in young males with onset of gynecomastia. I'll outline it below, and also compare the half-life graphs between it and the above Aromasin (Exemestane) case study in young males.
Again, here's the link to the Aromasin case study that I previously linked to above:
**broken link removed**
And here is the case study for Arimidex in boys:
**broken link removed**
Pharmacokinetics and Pharmacodynamics of Anastrozole in Pubertal Boys with Recent-Onset Gynecomastia
Abstract
Context: Use of aromatase inhibitors to suppress estrogen production is being actively investigated in a variety of experimental conditions in both females and males. Anastrozole (Arimidex) is a potent and selective reversible inhibitor of the aromatase enzyme in females.
Objective: Our objective was to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of anastrozole in adolescent males with gynecomastia of less than 1 yr duration. The effect of anastrozole on breast size was also assessed as an exploratory aim.
Design: We conducted a PK/PD open-label study.
Setting: This clinical research center study was undertaken at pediatric academic centers.
Patients: Forty-two boys with gynecomastia (mean age 13 ± 1.8 yr; duration of gynecomastia 7.0 ± 2.5 months; body mass index 28.3 ± 5.9 kg/m2) were recruited.
Interventions: Anastrozole, 1 mg, was given daily for 6 months.
Main Outcomes: We assessed PK/PD of anastrozole after 14 d daily dosing and changes in breast size (exploratory aim) by manual tape measurements (area) and ultrasound (volume) after 6 months.
Results: Anastrozole was rapidly absorbed orally (time to reach maximum concentration, 1 h) with a slow apparent clearance of 1.54 liters/h and a terminal half-life of 46.8 h. Testosterone/estradiol ratios increased significantly with concomitant increase in LH/FSH concentrations indicating aromatase blockade. There was a reduction in breast area (∼63%) and breast volume (∼57%) in the study group as compared with baseline (P = 0.004). The drug was well tolerated.
Conclusions: Anastrozole is a potent aromatase inhibitor in adolescent males, with rapid absorption and slow elimination kinetics after oral dosing. Exploratory analysis of changes in breast size showed breast reduction in the cohort; this deserves further study.
Now, where one has to be careful with that above is statements of the terminal half-life of Arimidex in males being 46.8 hours. However, for a body-builder's particular use, when you look at the graphs (below) from both the case studies above of Arimidex and Aromasin half-lifes in males, you can clearly see a massive drop (approx. 50%) in circulating levels of the drug by 4 hours, and yet another big drop by the 8 hour mark. Granted, the Aromasin graph was based on 1 single treatment, versus the Arimidex measurement done after 14 days. However, the trends follow near exact on both, including the maximum absorption rate of approx. 1 hour for either drug.
It is important to note that Aromasin is a suicidal AI, whereas Arimidex is not. Therefore, Aromasin has potentially a longer effect to inhibit aromatase due to its irreversible mechanism.
**broken link removed**
Exemestane plasma concentrations vs. time in 10 young males receiving a single 25-mg oral dose.
**broken link removed**
Anastrozole plasma concentrations over time after 14 d oral administration of anastrozole 1 mg once daily (population = 36).
All in all, my personal feelings is that males taking an AI should do such ED (every day), and not EOD (every other day), which would keep the blood plasma levels more stable, and less chance of estrogen rebound effect. It is important that anyone using an AI to have blood work performed at least during and after cycle to ensure dosages are proper and ultimately safe.